- Case Report
- Open Access
Progressive multifocal leukoencephalopathy in a patient without apparent immunosuppression
© Vaklavas et al; licensee BioMed Central Ltd. 2010
Received: 26 May 2010
Accepted: 28 September 2010
Published: 28 September 2010
An 80-year-old man with no history of an immune-compromising disorder was diagnosed with progressive multifocal leukoencephalopathy (PML). He presented with dysphagia and left-sided weakness; magnetic resonance imaging demonstrated marked signal abnormality in the subcortical white matter of the left frontal lobe and in the posterior limb of the right internal capsule. Polymerase chain reaction (PCR) analysis of the cerebrospinal fluid (CSF) was negative for John Cunningham (JC) virus. On brain biopsy, foamy macrophages infiltrating the white matter were identified, staining positive for anti-simian virus 40 antibodies. Postoperatively, PCR for JC viral DNA in the CSF was positive, establishing the diagnosis of PML. Extensive investigation for an occult immunocompromising disorder was negative. The patient's neurologic deficits rapidly increased throughout his hospital stay, and he died 3.5 months after his diagnosis.
Progressive multifocal leukoencephalopathy (PML) is a rapidly advancing demyelinating disorder of the central nervous system almost exclusively encountered in immunocompromised individuals. It is caused by reactivation of the John Cunningham virus (JCV) under conditions of cellular immunocompromise such as those encountered in patients with acquired immunodeficiency syndrome (AIDS), patients with hematologic and solid organ malignancies receiving chemotherapy, and transplant recipients under immunosuppression. The interest in this disease has recently increased because of its association with natalizumab, a monoclonal antibody directed against α4 integrins that is used to treat Crohn's disease and multiple sclerosis.
Here, we describe a rare occurrence of PML, with a rapidly fatal outcome, in a patient without an apparent history of immunosuppression.
An 80-year-old white man with a medical history of hypertension presented to the emergency department of an outside hospital after sustaining a fall. He had begun to drag his left leg at least one month prior to presentation, and over the preceding 5 days he had started to use a walker. The left-sided weakness was accompanied by progressive dysphagia, which occurred initially with fast eating and later with a regular eating rate. He had lost 35 lbs over the preceding 3 months. He had visited the emergency center monthly in the preceding 3 months because of falls. The patient was started on aspirin 25 mg/extended-release dipyridamole (Aggrenox®) 200 mg PO daily for suspected transient ischemic attacks.
At the time of presentation at Tyler County Hospital on May 16, 2008, a computed tomography (CT) of the patient's head demonstrated multiple cerebrovascular accidents. Cerebral atrophy and old infarcts in the right internal capsule, right cerebral peduncle, right thalamus, and left frontal lobe were identified. The patient was transferred from Tyler County Hospital in Woodville, Texas, to Christus St. Elizabeth Hospital in Beaumont, Texas, for a higher level of care.
Upon physical examination by the physicians at Christus St. Elizabeth Hospital, the patient's blood pressure was 158/81 mmHg, his respiratory rate 12 breaths per minute, heart rate 90 beats per minute, and temperature 37°Celsius. The patient was described as a cachectic Caucasian man, alert, awake, and oriented to person, time, and place. His speech was fluent; comprehension, naming, and repetition were intact. Examination of the cranial nerves showed mild drooping of the left angle of the mouth; all other cranial nerves were intact. Left hemiparesis was noted; motor strength was 4+/5 on the left symmetrically in the upper and lower extremities and 5-/5 in the right extremities. Deep tendon reflexes were hyperactive, but no extensor plantar responses were recorded. On admission to Christus St. Elizabeth Hospital, complete blood count and chemistry levels were normal, except for blood urea nitrogen and serum creatinine levels of 37 mg/dL and 2.4 mg/dL, respectively, indicating acute or chronic nephropathy. There was no history of renal insufficiency.
On his second hospital day, a magnetic resonance imaging (MRI) study of the brain without contrast demonstrated ill-defined white matter edema involving the right thalamus and left paramidline frontal lobe (sparing the cortex) and extending into the right cerebral peduncle. The lesions appeared bright on fluid-attenuated inversion recovery (FLAIR) sequences and diffusion images.
The findings raised concern about an underlying malignancy. Clinical findings and imaging studies (CT of the chest/abdomen/pelvis) did not, however, demonstrate any suspicious lesions. Immunofixation analysis was negative for antineuronal nuclear antibodies type 1 (anti-Hu) and 2 (anti-Ri). Renal and transrectal ultrasonography were conducted on the third inpatient day, prompted by the patient's newly diagnosed renal insufficiency, without contributory findings. A spinal tap yielded clear, colorless cerebrospinal fluid (CSF) with the following component levels: glucose 55 mg/dL (serum level, 88 mg/dL) and protein 31 mg/dL. Gram staining and culture were negative. On cytospin preparations, 10 cells were collected: 70% normal lymphocytes and 30% monocytes. A specimen was sent for polymerase chain reaction (PCR) analysis for JC virus and herpes simplex virus; both studies were negative. The CSF was also negative for the presence of Borrelia burgdorferi antigens. Myelin basic protein was elevated (12.63 ng/mL, reference < 4 ng/mL); no oligoclonal bands were identified. An electroencephalogram demonstrated mild bifrontal slowing, more prominent on the left than the right. A carotid Doppler ultrasound was normal. Serum and urine protein electrophoreses were consistent with proteinuria of glomerular pattern but negative for the presence of paraprotein.
On day 11, the patient experienced deterioration of his neurologic symptoms. On neurologic examination, the patient was awake but drowsy and oriented to time, place, and person. Mild left facial nerve palsy was again noted. Motor strength was 5/5 on the right, whereas on the left there was progressive weakness; motor strength was 2/5 on the left hand, 4-/5 on the left biceps, and 4-/5 over the left leg. Deep tendon reflexes were 2+, and no extensor plantar responses were reported. Coordination was normal on the right side, whereas some ataxia was recorded on the left. MRI without contrast of the cervical, thoracic, and lumbar spine on day 12 demonstrated no major stenosis or neural impingement. MRI of the brain on day 13 demonstrated two areas of abnormal signals on diffusion-weighted imaging (left frontal lobe measuring 2.7 × 2.7 cm and right thalamus and basal ganglion measuring 1.6 × 1.2 cm). FLAIR images were positive in these areas and in several other small areas elsewhere. No significant change was identified when this study was compared with the one obtained on the second inpatient day.
A brain biopsy was considered, and the patient was transferred to Memorial Hermann Hospital, Houston, Texas, on June 6, 2008. On admission, his vital signs were within normal limits. He was described as a cachectic Caucasian man with a poor performance status. His neurologic examination was remarkable for left facial drooping and left-sided weakness (1/5 in the left upper and 2/5 in the left lower extremity). Deep tendon reflexes were hyperactive on the left side and normal on the right side. In addition, pinprick, hot and cold, light touch, and vibratory sensation and proprioception were decreased on the left side. Gait could not be assessed due to his left motor weakness. His Folstein Mini Mental State Examination score was 23/30; orientation was intact, whereas registration (1/3) and recollection (0/3) were severely affected.
This unexpected finding spawned a thorough investigation for an occult immunocompromising disorder. Testing for the human immunodeficiency virus (HIV) was negative by enzyme immunoassay (twice) and PCR. The patient's CD4 count was 332 cells/μl (normal range, 410-1590 cells/μl) and his CD8 count was 485 cells/μl (normal range, 190-1140 cells/μl), as measured by flow cytometry. Testing for other infectious causes (toxoplasmosis, hepatitides, Cryptococcus, human T-lymphotropic virus I and II) was also negative. His persistent lymphopenia (absolute lymphocyte count throughout the hospital course ranged between 120 and 1077 cells/μl) raised the suspicion for a rheumatologic disease. Athough his antinuclear antibody titer was high (1:1280), he did not meet any clinical criteria for lupus erythematosus. Testing for anti-Ro and anti-La autoantibodies was positive, but the absence of xerostomia/xerophthalmia and a negative biopsy of minor salivary glands did not substantiate the diagnosis of Sjögren syndrome. The rest of the rheumatologic testing (anti-double-stranded DNA, cyclic citrullinated peptide, anti-smooth muscle and anti-RNP antibodies; rapid plasma reagin; complement 3 and 4 levels) was unrevealing. A bone marrow biopsy revealed variable cellularity (10-30%), with trilineage hematopoiesis and increased iron stores. There was no morphologic evidence of malignancy. Stains and cultures for acid-fast bacilli and fungi and cultures for cytomegalovirus were negative. The chromosomal analysis was negative as well.
Throughout the rest of his hospital stay, the patient's neurologic condition continued to deteriorate. His course was marked by an episode of altered mental status, progressive dementia, motor weakness, declining visual acuity, and worsening performance status. He was discharged to a skilled nursing facility closer to home, where he died 3.5 months after the diagnosis of PML.
Progressive multifocal leukoencephalopathy was originally described in 1958 in two patients with chronic lymphocytic leukemia and one patient with Hodgkin's disease. The causative agent, the JC virus, was isolated in 1971 from the brain of a patient with Hodgkin's disease, and the virus was named after him. With the advent of the HIV epidemic, PML was recognized as a major opportunistic infection of AIDS, but with effective antiretroviral therapy, its incidence and attributable mortality rates have decreased. Most recently, interest in PML has been revived by its association with natalizumab (Tysabri®), a promising new drug for the treatment of multiple sclerosis and Crohn's disease.
The occurrence of PML in persons without known immunosuppression is exceedingly rare. Although traditionally associated with conditions of cellular immunocompromise, the concept that profound cellular immunosuppression is required for the reactivation of the JC virus has recently been challenged . Although old age has been associated with idiopathic CD4+ lymphocytopenia, and the latter has been associated with PML,[10, 12] our patient did not meet the Centers for Disease Control and Prevention criteria for idiopathic CD4+ lymphocytopenia . With his lymphocyte count ranging between 120 and 1077 lymphocytes per microliter, however, it is possible that he had transient CD4+ lymphocytopenia. The association of aging with CD4+ lymphocytopenia and the high JCV seroprevalence in adults should increase awareness about the possible diagnosis of PML in the appropriate clinical and radiographic setting.
The initially negative PCR results for JC virus in the CSF, despite the suspicious radiologic findings, delayed the diagnosis. Negative PCR results for JCV-DNA in the CSF have been described in patients with AIDS, and a correlation with active antiretroviral treatment has been hypothesized. CSF obtained after open brain biopsy was positive for JCV-DNA, indicating that a breach in the blood-brain barrier or progressive infection may have led to the dissemination of the virus in the subarachnoid space. The fact that a negative PCR result for JCV-DNA cannot completely exclude PML has raised the need for a new consensus terminology, in which immunosuppressed patients with clinical and radiographic features consistent with PML and no alternative etiology should be considered as "possible PML".
The occurrence of PML in patients without identifiable immunodeficiency poses a challenge from a therapeutic perspective. While strategies to reverse immunodeficiency, such as discontinuation of immunosuppressive therapy, institution of antiretroviral therapy in HIV-positive patients, plasma exchange and immunoadsorption in natalizumab treated patients , work well in certain groups, no treatment options of proven efficacy exist for patients without a clear immune disorder. Cytarabine, cidofovir, topotecan, and mirtazapine have been investigated as therapeutic agents, mostly in patients with AIDS, with variable results and toxicities. A study to investigate the effects of mefloquine in PML is currently ongoing.
A consent has been waived by the Institutional Review Board for the publication of this case report.
The authors are thankful to the other physicians and nursing staff who participated in the care of this patient.
- Koralnik IJ: New insights into progressive multifocal leukoencephalopathy. Curr Opin Neurol 2004, 17: 365-370. 10.1097/00019052-200406000-00019PubMedView ArticleGoogle Scholar
- Koralnik IJ: Progressive multifocal leukoencephalopathy revisited: Has the disease outgrown its name? Ann Neurol 2006, 60: 162-173. 10.1002/ana.20933PubMedView ArticleGoogle Scholar
- Van Assche G, Van Ranst M, Sciot R, Dubois B, Vermeire S, Noman M, Verbeeck J, Geboes K, Robberecht W, Rutgeerts P: Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med 2005, 353: 362-368. 10.1056/NEJMoa051586PubMedView ArticleGoogle Scholar
- Kleinschmidt-DeMasters BK, Tyler KL: Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med 2005, 353: 369-374. 10.1056/NEJMoa051782PubMedView ArticleGoogle Scholar
- Dalianis T, Ramqvist T, Andreasson K, Kean JM, Garcea RL: KI, WU and Merkel cell polyomaviruses: a new era for human polyomavirus research. Semin Cancer Biol 2009, 19: 270-275. 10.1016/j.semcancer.2009.04.001PubMedView ArticleGoogle Scholar
- Astrom KE, Mancall EL, Richardson EP Jr: Progressive multifocal leuko-encephalopathy; a hitherto unrecognized complication of chronic lymphatic leukaemia and Hodgkin's disease. Brain 1958, 81: 93-111. 10.1093/brain/81.1.93PubMedView ArticleGoogle Scholar
- Padgett BL, Walker DL, ZuRhein GM, Eckroade RJ, Dessel BH: Cultivation of papova-like virus from human brain with progressive multifocal leucoencephalopathy. Lancet 1971, 1: 1257-1260. 10.1016/S0140-6736(71)91777-6PubMedView ArticleGoogle Scholar
- Berger JR, Kaszovitz B, Post MJ, Dickinson G: Progressive multifocal leukoencephalopathy associated with human immunodeficiency virus infection. A review of the literature with a report of sixteen cases. Ann Intern Med 1987, 107: 78-87.PubMedView ArticleGoogle Scholar
- Khanna N, Elzi L, Mueller NJ, Garzoni C, Cavassini M, Fux CA, Vernazza P, Bernasconi E, Battegay M, Hirsch HH: Incidence and outcome of progressive multifocal leukoencephalopathy over 20 years of the Swiss HIV Cohort Study. Clin Infect Dis 2009, 48: 1459-1466. 10.1086/598335PubMedView ArticleGoogle Scholar
- Gheuens S, Pierone G, Peeters P, Koralnik IJ: Progressive multifocal leukoencephalopathy in individuals with minimal or occult immunosuppression. J Neurol Neurosurg Psychiatry 81: 247-254. 10.1136/jnnp.2009.187666Google Scholar
- Rea IM, Alexander HD, Crockard AD, Morris TC: CD4 lymphopenia in very elderly people. Lancet 1996, 347: 328-329.PubMedGoogle Scholar
- Zonios DI, Falloon J, Bennett JE, Shaw PA, Chaitt D, Baseler MW, Adelsberger JW, Metcalf JA, Polis MA, Kovacs SJ, et al.: Idiopathic CD4+ lymphocytopenia: natural history and prognostic factors. Blood 2008, 112: 287-294. 10.1182/blood-2007-12-127878PubMedPubMed CentralView ArticleGoogle Scholar
- Smith DK, Neal JJ, Holmberg SD: Unexplained opportunistic infections and CD4+ T-lymphocytopenia without HIV infection. An investigation of cases in the United States. The Centers for Disease Control Idiopathic CD4+ T-lymphocytopenia Task Force. N Engl J Med 1993, 328: 373-379. 10.1056/NEJM199302113280601PubMedView ArticleGoogle Scholar
- Stolt A, Sasnauskas K, Koskela P, Lehtinen M, Dillner J: Seroepidemiology of the human polyomaviruses. J Gen Virol 2003, 84: 1499-1504. 10.1099/vir.0.18842-0PubMedView ArticleGoogle Scholar
- Antinori A, Cingolani A, Lorenzini P, Giancola ML, Uccella I, Bossolasco S, Grisetti S, Moretti F, Vigo B, Bongiovanni M, et al.: Clinical epidemiology and survival of progressive multifocal leukoencephalopathy in the era of highly active antiretroviral therapy: data from the Italian Registry Investigative Neuro AIDS (IRINA). J Neurovirol 2003,9(Suppl 1):47-53.PubMedView ArticleGoogle Scholar
- Wenning W, Haghikia A, Laubenberger J, Clifford DB, Behrens PF, Chan A, Gold R: Treatment of progressive multifocal leukoencephalopathy associated with natalizumab. N Engl J Med 2009, 361: 1075-1080. 10.1056/NEJMoa0810257PubMedView ArticleGoogle Scholar
- Aksamit AJ: Progressive multifocal leukoencephalopathy. Curr Treat Options Neurol 2008, 10: 178-185. 10.1007/s11940-008-0019-8PubMedView ArticleGoogle Scholar
- Hall CD, Dafni U, Simpson D, Clifford D, Wetherill PE, Cohen B, McArthur J, Hollander H, Yainnoutsos C, Major E, et al.: Failure of cytarabine in progressive multifocal leukoencephalopathy associated with human immunodeficiency virus infection. AIDS Clinical Trials Group 243 Team. N Engl J Med 1998, 338: 1345-1351. 10.1056/NEJM199805073381903PubMedView ArticleGoogle Scholar
- De Luca A, Ammassari A, Pezzotti P, Cinque P, Gasnault J, Berenguer J, Di Giambenedetto S, Cingolani A, Taoufik Y, Miralles P, et al.: Cidofovir in addition to antiretroviral treatment is not effective for AIDS-associated progressive multifocal leukoencephalopathy: a multicohort analysis. Aids 2008, 22: 1759-1767. 10.1097/QAD.0b013e32830a5043PubMedView ArticleGoogle Scholar
- Royal W, Dupont B, McGuire D, Chang L, Goodkin K, Ernst T, Post MJ, Fish D, Pailloux G, Poncelet H, et al.: Topotecan in the treatment of acquired immunodeficiency syndrome-related progressive multifocal leukoencephalopathy. J Neurovirol 2003, 9: 411-419. 10.1080/713831540PubMedView ArticleGoogle Scholar
- Cettomai D, McArthur JC: Mirtazapine use in human immunodeficiency virus-infected patients with progressive multifocal leukoencephalopathy. Arch Neurol 2009, 66: 255-258. 10.1001/archneurol.2008.557PubMedView ArticleGoogle Scholar
- Study to Explore the Effect of Mefloquine in Subjects With Progressive Multifocal Leukoencephalopathy (PML)[http://www.virologyj.com/content/7/1/256] --- Either ISSN or Journal title must be supplied.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.